“…Reports of leflunomide to treat immune‐mediated diseases in dogs are limited to a few case series including dogs with immune‐mediated polyarthritis (IMPA), inflammatory colorectal polyps, immune‐mediated haemolytic anaemia (IMHA), canine reactive histiocytosis, erosive IMPA and Evans' Syndrome (Affolter & Moore, 2000; Bianco & Hardy, 2009; Colopy et al., 2010; Fukushima et al., 2016; Gregory et al., 1998; Sato et al., 2017; Shaughnessy et al., 2016; Tani et al., 2020; Weingart et al., 2019). In total, 21 dogs with naITP treated with leflunomide are reported in literature at the time of writing (Gregory et al., 1998; Sato et al., 2017; Scuderi et al., 2016).…”